Correlation of serum amyloid-A levels, clinical manifestations, treatment, and disease activity in patients with behçet’s disease

Jurgen Sota, Antonio Vitale, Donato Rigante, Ida Orlando, Orso Maria Lucherini, Antonella Simpatico, Giuseppe Lopalco, Rossella Franceschini, Mauro Galeazzi, Bruno Frediani, Claudia Fabiani, Gian Marco Tosi, Luca Cantarini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Behçet’s disease (BD) is an inflammatory disorder potentially leading to life-and sight-threatening complications. No laboratory marker associated with disease activity or predicting the occurrence of disease manifestations is currently available. Objectives: To determine an association between serum amyloid-A (SAA) levels and disease activity via the BD Current Activity Form (BDCAF), to evaluate disease activity in relation to different SAA thresholds, to examine the association between single organ involvement and the overall major organ involvement with different SAA thresholds, and to assess the influence of biologic therapy on SAA levels. Methods: We collected 95 serum samples from 64 BD patients. Related demographic, clinical, and therapeutic data were retrospectively gathered. Results: No association was identified between SAA levels and BD disease activity (Spearman’s rho = 0.085, P = 0.411). A significant difference was found in the mean BDCAF score between patients presenting with SAA levels < 200 mg/L and those with SAA levels > 200 mg/L (P = 0.027). SAA levels > 200 mg/L were associated with major organ involvement (P = 0.008). A significant association was found between SAA levels > 150 mg/dl and ocular (P = 0.008), skin (P = 0.002), and mucosal (P = 0.012) manifestations. Patients undergoing biologic therapies displayed more frequently SAA levels < 200 mg/L vs. patients who were not undergoing biologic therapies (P = 0.012). Conclusions: Although SAA level does not represent a biomarker for disease activity, it might be a predictor of major organ involvement and ocular disease relapse at certain thresholds in patients with BD.

Original languageEnglish
Pages (from-to)517-521
Number of pages5
JournalIsrael Medical Association Journal
Volume20
Issue number8
Publication statusPublished - Jan 1 2018

Fingerprint

Serum Amyloid A Protein
Biological Therapy
Therapeutics
Biomarkers
Eye Diseases
Demography

Keywords

  • Behçet’s disease
  • Behçet’s disease current activity form (BDCAF)
  • Biomarkers
  • Serum amyloid-A (SAA)
  • Uveitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Correlation of serum amyloid-A levels, clinical manifestations, treatment, and disease activity in patients with behçet’s disease. / Sota, Jurgen; Vitale, Antonio; Rigante, Donato; Orlando, Ida; Lucherini, Orso Maria; Simpatico, Antonella; Lopalco, Giuseppe; Franceschini, Rossella; Galeazzi, Mauro; Frediani, Bruno; Fabiani, Claudia; Tosi, Gian Marco; Cantarini, Luca.

In: Israel Medical Association Journal, Vol. 20, No. 8, 01.01.2018, p. 517-521.

Research output: Contribution to journalArticle

Sota, J, Vitale, A, Rigante, D, Orlando, I, Lucherini, OM, Simpatico, A, Lopalco, G, Franceschini, R, Galeazzi, M, Frediani, B, Fabiani, C, Tosi, GM & Cantarini, L 2018, 'Correlation of serum amyloid-A levels, clinical manifestations, treatment, and disease activity in patients with behçet’s disease', Israel Medical Association Journal, vol. 20, no. 8, pp. 517-521.
Sota, Jurgen ; Vitale, Antonio ; Rigante, Donato ; Orlando, Ida ; Lucherini, Orso Maria ; Simpatico, Antonella ; Lopalco, Giuseppe ; Franceschini, Rossella ; Galeazzi, Mauro ; Frediani, Bruno ; Fabiani, Claudia ; Tosi, Gian Marco ; Cantarini, Luca. / Correlation of serum amyloid-A levels, clinical manifestations, treatment, and disease activity in patients with behçet’s disease. In: Israel Medical Association Journal. 2018 ; Vol. 20, No. 8. pp. 517-521.
@article{6af5284f2c424f76bdcf0f72c3ed8493,
title = "Correlation of serum amyloid-A levels, clinical manifestations, treatment, and disease activity in patients with beh{\cc}et’s disease",
abstract = "Background: Beh{\cc}et’s disease (BD) is an inflammatory disorder potentially leading to life-and sight-threatening complications. No laboratory marker associated with disease activity or predicting the occurrence of disease manifestations is currently available. Objectives: To determine an association between serum amyloid-A (SAA) levels and disease activity via the BD Current Activity Form (BDCAF), to evaluate disease activity in relation to different SAA thresholds, to examine the association between single organ involvement and the overall major organ involvement with different SAA thresholds, and to assess the influence of biologic therapy on SAA levels. Methods: We collected 95 serum samples from 64 BD patients. Related demographic, clinical, and therapeutic data were retrospectively gathered. Results: No association was identified between SAA levels and BD disease activity (Spearman’s rho = 0.085, P = 0.411). A significant difference was found in the mean BDCAF score between patients presenting with SAA levels < 200 mg/L and those with SAA levels > 200 mg/L (P = 0.027). SAA levels > 200 mg/L were associated with major organ involvement (P = 0.008). A significant association was found between SAA levels > 150 mg/dl and ocular (P = 0.008), skin (P = 0.002), and mucosal (P = 0.012) manifestations. Patients undergoing biologic therapies displayed more frequently SAA levels < 200 mg/L vs. patients who were not undergoing biologic therapies (P = 0.012). Conclusions: Although SAA level does not represent a biomarker for disease activity, it might be a predictor of major organ involvement and ocular disease relapse at certain thresholds in patients with BD.",
keywords = "Beh{\cc}et’s disease, Beh{\cc}et’s disease current activity form (BDCAF), Biomarkers, Serum amyloid-A (SAA), Uveitis",
author = "Jurgen Sota and Antonio Vitale and Donato Rigante and Ida Orlando and Lucherini, {Orso Maria} and Antonella Simpatico and Giuseppe Lopalco and Rossella Franceschini and Mauro Galeazzi and Bruno Frediani and Claudia Fabiani and Tosi, {Gian Marco} and Luca Cantarini",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "20",
pages = "517--521",
journal = "Israel Medical Association Journal",
issn = "1565-1088",
publisher = "Israel Medical Association",
number = "8",

}

TY - JOUR

T1 - Correlation of serum amyloid-A levels, clinical manifestations, treatment, and disease activity in patients with behçet’s disease

AU - Sota, Jurgen

AU - Vitale, Antonio

AU - Rigante, Donato

AU - Orlando, Ida

AU - Lucherini, Orso Maria

AU - Simpatico, Antonella

AU - Lopalco, Giuseppe

AU - Franceschini, Rossella

AU - Galeazzi, Mauro

AU - Frediani, Bruno

AU - Fabiani, Claudia

AU - Tosi, Gian Marco

AU - Cantarini, Luca

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Behçet’s disease (BD) is an inflammatory disorder potentially leading to life-and sight-threatening complications. No laboratory marker associated with disease activity or predicting the occurrence of disease manifestations is currently available. Objectives: To determine an association between serum amyloid-A (SAA) levels and disease activity via the BD Current Activity Form (BDCAF), to evaluate disease activity in relation to different SAA thresholds, to examine the association between single organ involvement and the overall major organ involvement with different SAA thresholds, and to assess the influence of biologic therapy on SAA levels. Methods: We collected 95 serum samples from 64 BD patients. Related demographic, clinical, and therapeutic data were retrospectively gathered. Results: No association was identified between SAA levels and BD disease activity (Spearman’s rho = 0.085, P = 0.411). A significant difference was found in the mean BDCAF score between patients presenting with SAA levels < 200 mg/L and those with SAA levels > 200 mg/L (P = 0.027). SAA levels > 200 mg/L were associated with major organ involvement (P = 0.008). A significant association was found between SAA levels > 150 mg/dl and ocular (P = 0.008), skin (P = 0.002), and mucosal (P = 0.012) manifestations. Patients undergoing biologic therapies displayed more frequently SAA levels < 200 mg/L vs. patients who were not undergoing biologic therapies (P = 0.012). Conclusions: Although SAA level does not represent a biomarker for disease activity, it might be a predictor of major organ involvement and ocular disease relapse at certain thresholds in patients with BD.

AB - Background: Behçet’s disease (BD) is an inflammatory disorder potentially leading to life-and sight-threatening complications. No laboratory marker associated with disease activity or predicting the occurrence of disease manifestations is currently available. Objectives: To determine an association between serum amyloid-A (SAA) levels and disease activity via the BD Current Activity Form (BDCAF), to evaluate disease activity in relation to different SAA thresholds, to examine the association between single organ involvement and the overall major organ involvement with different SAA thresholds, and to assess the influence of biologic therapy on SAA levels. Methods: We collected 95 serum samples from 64 BD patients. Related demographic, clinical, and therapeutic data were retrospectively gathered. Results: No association was identified between SAA levels and BD disease activity (Spearman’s rho = 0.085, P = 0.411). A significant difference was found in the mean BDCAF score between patients presenting with SAA levels < 200 mg/L and those with SAA levels > 200 mg/L (P = 0.027). SAA levels > 200 mg/L were associated with major organ involvement (P = 0.008). A significant association was found between SAA levels > 150 mg/dl and ocular (P = 0.008), skin (P = 0.002), and mucosal (P = 0.012) manifestations. Patients undergoing biologic therapies displayed more frequently SAA levels < 200 mg/L vs. patients who were not undergoing biologic therapies (P = 0.012). Conclusions: Although SAA level does not represent a biomarker for disease activity, it might be a predictor of major organ involvement and ocular disease relapse at certain thresholds in patients with BD.

KW - Behçet’s disease

KW - Behçet’s disease current activity form (BDCAF)

KW - Biomarkers

KW - Serum amyloid-A (SAA)

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=85055128084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055128084&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 517

EP - 521

JO - Israel Medical Association Journal

JF - Israel Medical Association Journal

SN - 1565-1088

IS - 8

ER -